103 related articles for article (PubMed ID: 8678495)
1. [Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer].
Nomura Y; Tashiro H; Shirouzu M; Takayama T
Gan To Kagaku Ryoho; 1996 Mar; 23(4):439-45. PubMed ID: 8678495
[TBL] [Abstract][Full Text] [Related]
2. Mitomycin C, methotrexate, and vincristine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer--a randomized control study.
Tashiro H; Nomura Y
Anticancer Res; 1995; 15(5B):2229-37. PubMed ID: 8572630
[TBL] [Abstract][Full Text] [Related]
3. [Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin].
Nomura Y; Kanda K; Tashiro H; Hamada Y; Saeki K
Gan To Kagaku Ryoho; 1983 Mar; 10(3):824-8. PubMed ID: 6411002
[TBL] [Abstract][Full Text] [Related]
4. Response to second line chemo-endocrine treatment may prolong the overall survival of advanced breast cancer patients.
Nomura Y
Anticancer Res; 1997; 17(2B):1425-30. PubMed ID: 9137509
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
[TBL] [Abstract][Full Text] [Related]
6. [Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer].
Maeda T; Kubo Y; Sasajima T; Ikeda K; Hirata S; Yamazaki K; Nakajima S
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2165-9. PubMed ID: 8239681
[TBL] [Abstract][Full Text] [Related]
7. [A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
Yokota T; Fujii T; Roppongi T; Kanno K; Ogata T
Gan To Kagaku Ryoho; 1998 Apr; 25(5):739-42. PubMed ID: 9571973
[TBL] [Abstract][Full Text] [Related]
8. [Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report].
Izumi M; Iino Y; Yokoe T; Inoue T; Yamada T; Kobayashi I; Andoh T; Yokota T; Iijima T; Morishita Y
Gan To Kagaku Ryoho; 1994 Feb; 21(2):265-8. PubMed ID: 8311500
[TBL] [Abstract][Full Text] [Related]
9. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).
Beex L; Rose C; Mouridsen H; Jassem J; Nooij M; Estape J; Paridaens R; Piccart M; Gorlia T; Lardenoije S; Baila L
Eur J Cancer; 2006 Dec; 42(18):3178-85. PubMed ID: 17045796
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancer.
Raina V; Sharma A; Deo SV; Shukla NK; Mohanty BK; Goel A; Rath GK
J Assoc Physicians India; 1998 Nov; 46(11):926-9. PubMed ID: 11229215
[TBL] [Abstract][Full Text] [Related]
11. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K
Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831
[TBL] [Abstract][Full Text] [Related]
12. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy.
Blumenschein GR; DiStefano A; Caderao J; Fristenberg B; Adams J; Schweichler LH; Drinkard L
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2633-7. PubMed ID: 10068266
[TBL] [Abstract][Full Text] [Related]
13. [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
Mitsuyama S; Ohno S; Koga T; Takayama T; Yamashita J; Ogawa M; Shirouzu K; Sugimachi K; Nomura Y; Ogawa N
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2029-36. PubMed ID: 10584567
[TBL] [Abstract][Full Text] [Related]
14. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
Kim R; Osaki A; Tanabe K; Kojima J; Toge T
Oncol Rep; 2001; 8(3):597-603. PubMed ID: 11295087
[TBL] [Abstract][Full Text] [Related]
16. [Chemo-endocrine therapy of advanced breast cancer].
Nomura Y
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3214-20. PubMed ID: 2973769
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
18. [CMF or CAF combination chemotherapy for breast cancer].
Ota J
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1886-90. PubMed ID: 8978791
[TBL] [Abstract][Full Text] [Related]
19. Mitomycin: its evolving role in the treatment of breast cancer.
Hortobagyi GN
Oncology; 1993 Apr; 50 Suppl 1():1-8. PubMed ID: 8483556
[TBL] [Abstract][Full Text] [Related]
20. [A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer].
Ferrero JM; Namer M; Dufour JF; Largillier R; Creisson A; Teissier E; Machiavello JC; Lallement M; Monticelli J; Abbes M
Bull Cancer; 1997 Jan; 84(1):10-6. PubMed ID: 9180853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
